Nature Medicine, Published online: 22 July 2026; doi:10.1038/s41591-026-04522-3
In a phase 1 trial, the maximum tolerated dose for an FcRH5-containing bispecific T cell engager was not reached, and there was an encouraging response rate in patients with relapsed or refractory multiple myeloma.
